Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked diligently but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past few shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set out what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire interview which I came away with a bad viewpoint of the business.

Irony of irony, my poor impression of the business enterprise has grown steadily, yet the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this technology and associated intellectual property coming from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) as well as the first new drug application approval ($five million), and also royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to get a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and multiple therapies, it’s this individual treatment in addition to a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an active company with diverse interests albeit focused on leronlimab, multiple illness types, multiple publications and multiple delivering presentations.

Can all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself through the very start of the interest of mine in this organization. Judging by way of the multiples of thousands of several commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *